N Payne - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

N Payne

Showing results (391-400 of 393) with videos related to

Pageof 40

Sort By:

You have reached the last page of results.This site can display upto 393 results.

Molecular Cancer Therapeutics|November 15, 2018

MTORC1/2 Inhibition as a Therapeutic Strategy for <i>PIK3CA</i> Mutant CancersStephanie L Fricke, Susan N Payne, Peter F Favreau, et al.

Molecular Cancer Therapeutics|July 10, 2025

BCL-2 family inhibition enhances MTORC1/2 inhibition in PIK3CA mutant colorectal cancerRebecca A DeStefanis, Alexa E Schmitz, Alyssa K Steimle, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 9, 2019

Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and RadiationCheri A Pasch, Peter F Favreau, Alexander E Yueh, et al.

Pageof 40

Search research articles

Showing results (391-400 of 393) with videos related to

Sort By:

Pageof 40

You have reached the last page of results.This site can display upto 393 results.

Molecular Cancer Therapeutics|November 15, 2018

MTORC1/2 Inhibition as a Therapeutic Strategy for <i>PIK3CA</i> Mutant CancersStephanie L Fricke, Susan N Payne, Peter F Favreau, et al.

Molecular Cancer Therapeutics|July 10, 2025

BCL-2 family inhibition enhances MTORC1/2 inhibition in PIK3CA mutant colorectal cancerRebecca A DeStefanis, Alexa E Schmitz, Alyssa K Steimle, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 9, 2019

Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and RadiationCheri A Pasch, Peter F Favreau, Alexander E Yueh, et al.

Pageof 40